Historique
Article de Périodique
Potential for abuse of buprenorphine in office-based treatment of opioid dependence (2005)
Auteur(s) :
CICERO, T. J. ;
INCIARDI, J. A.
Année
2005
Page(s) :
1863-1865
Langue(s) :
Anglais
Domaine :
Drogues illicites / Illicit drugs
Résumé :
To the Editor: Buprenorphine was approved by the Food and Drug Administration (FDA) in 2002 for the treatment of opioid addiction in certified physicians' offices. However, the FDA and the Drug Enforcement Administration (DEA) expressed concern that the use of buprenorphine in opioid-dependent populations would inevitably lead to its diversion and abuse. Thus, buprenorphine was moved from Schedule V of the Controlled Substances Act to Schedule III. In an effort to restrict the number of persons exposed to the drug, a limit was imposed of no more than 30 patients per qualifying certified physician.
Affiliation :
Washington University, St. Louis, MO, USA